US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore
Ulcerative colitis (UC) is a type of an inflammatory bowel disease (IBD). Ulcerative colitis and Crohn’s disease are the most common type of the IBD. Both diseases affect the GI system with similar symptoms while the course of the diseases and treatments may be different. UC usually affects large intestine (rectum and colon), while CD can affect any part of the GI tract.
UC causes an inflammation and cores (ulcers) in the colon and usually affects the sigmoid colon (lower section of a large intestine) and rectum. The disease may affect people at any age, but usually it is diagnosed in people before the age of 30. UC can be controlled with medication and in severe cases can even be treated by a surgical removal of the entire large intestine.
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- COMPETITIVE LANDSCAPE
- MARKET TRENDS
- KEY MARKET DEVELOPMENTS
- MARKETS INCLUDED
- 1.1 VERSION HISTORY
- IDATA PHARMA’S 9-STEP METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecasts and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
- MECHANISM OF ACTION
- 3.1 INTRODUCTION
- 3.1.1 Tumor Necrosis Factor (TNF)
- 3.1.2 B-cell Inhibitors
- 3.1.3 Interleukin Inhibitors
- 3.1.4 Janus Kinase Inhibitors
- 3.1.5 Co-stimulation Modulators
- PRODUCT ASSESSMENT
- 4.1 KEY MARKETED PRODUCTS
- 4.1.1 Abatacept (ORENCIA®)
- 4.1.1.1 Future Developments
- 4.1.1.2 Currently Marketed Products by Company
- 4.1.2 Adalimumab (HUMIRA®)
- 4.1.2.1 Future Developments
- 4.1.2.2 Currently Marketed Products by Company
- 4.1.3 Certolizumab pegol (CIMZIA®)
- 4.1.3.1 Future Developments
- 4.1.3.2 Currently Marketed Products by Company
- 4.1.4 Etanercept (ENBREL®, Benepali®)
- 4.1.4.1 Future Developments
- 4.1.4.2 Currently Marketed Products by company
- 4.1.5 Golimumab (SIMPONI®)
- 4.1.5.1 Future Developments
- 4.1.5.2 Currently Marketed Products by company
- 4.1.6 Infliximab (REMICADE®, Inflectra®, Remsima®, Flixabi®, Renflexis®)
- 4.1.6.1 Future Developments
- 4.1.6.2 Currently Marketed Products by company
- 4.1.7 Natalizumab (TYSABRI®)
- 4.1.7.1 Currently Marketed Products by company
- 4.1.8 Rituximab (Rituxan®, MabThera®, Rixathon®, Truxima™)
- 4.1.8.1 Future Developments
- 4.1.8.2 Currently Marketed Products by company
- 4.1.9 Tocilizumab (Actemra®/RoActemra®)
- 4.1.9.1 Currently Marketed Products by company
- 4.1.10 Tofacitinib (XELJANZ®)
- 4.1.10.1 Future Developments
- 4.1.10.2 Currently Marketed Products by company
- 4.1.11 Ustekinumab (STELARA®)
- 4.1.11.1 Future Developments
- 4.1.11.2 Currently Marketed Products by company
- 4.1.12 Vedolizumab (ENTYVIO®)
- 4.1.12.1 Currently Marketed Products by company
- 4.2 KEY PRODUCTS IN PIPELINE
- 4.2.1 Barcitinb (Olumiant®)
- 4.2.2 Guselkumab (Tremfya™)
- 4.2.3 Cobitolimod (Kappaproct®)
- 4.2.4 Mavrilimumab
- 4.2.5 Sirukumab
- 4.2.6 Vobarilizumab
- 4.3 PRODUCTS IN DEVELOPMENT BY CORE COMPANIES
- 4.4 CLINICAL TRIAL BY DISEASE
- 4.4.1 Rheumatoid Arthritis
- 4.4.1.1 Study Completion Date: 2017
- 4.4.1.2 Study Completion Date: 2016
- 4.4.2 Crohn’s Disease (CD)
- 4.4.2.1 Study Completion Date: 2017
- 4.4.2.2 Study Completion Date: 2016
- 4.4.2.3 Study Completion Date: 2015
- 4.4.3 Ankylosing Spondylitis (AS)
- 4.4.3.1 Study Completion Date: 2017
- 4.4.3.2 Study Completion Date: 2016
- 4.4.3.3 Study Completion Date: 2015
- 4.4.4 Psoriasis (Ps)
- 4.4.4.1 Study Completion Date: 2017
- 4.4.4.2 Study Completion Date: 2016
- 4.4.5 Ulcerative Colitis (UC)
- 4.4.5.1 Study Completion Date: 2016
- 4.4.5.2 Study Completion Date: 2015
- COUNTRY PROFILE
- 5.1 UNITED STATES
- 5.1.1 Population and Demographics
- 5.1.2 Treatment Size Analysis for 2017
- 5.1.3 Drug Cost Analysis
- ULCERATIVE COLITIS MARKET
- 6.1 INTRODUCTION
- 6.1.1 Causes and Disease Progression
- 6.1.2 Diagnosis and Treatment Options
- 6.1.3 Symptoms and Complications
- 6.1.4 Epidemiology
- 6.2 MARKET OVERVIEW
- 6.3 TREND ANALYSIS
- 6.4 COMPETITIVE ANALYSIS
- ABBREVIATIONS
- APPENDIX: COMPANY PRESS RELEASES
- List of Charts
- Chart 2 1: Immunology Market by Segment, U.S., 2013 – 2023
- Chart 2 2: Immunology Market Overview, U.S., 2016 & 2023
- Chart 6 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024
- Chart 6 2: Ulcerative Colitis Market Breakdown, U.S., 2017
- Chart 6 3: Ulcerative Colitis Market Breakdown, U.S., 2024
- Chart 6 4: Growth Rates by Segment, Ulcerative Colitis Market, U.S., 2014 – 2024
- Chart 6 5: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
- List of Figures
- Figure 2 1: Immunology Market Share Ranking by Segment, U.S., 2017
- Figure 2 2: Companies Researched in this Report, U.S., 2017
- Figure 2 3: Factors Impacting the Immunology Market
- Figure 2 4: Recent Events in the Immunology Market, Global, 2016 – 2017, AbbVie
- Figure 2 5: Recent Events in the Immunology Market, Global, 2016 – 2017, Amgen
- Figure 2 6: Recent Events in the Immunology Market, Global, 2016 – 2017, AstraZeneca
- Figure 2 7: Recent Events in the Immunology Market, Global, 2016 – 2017, Biogen
- Figure 2 8: Recent Events in the Immunology Market, Global, 2016 – 2017, BMS
- Figure 2 9: Recent Events in the Immunology Market, Global, 2016 – 2017, Eli Lilly
- Figure 2 10: Recent Events in the Immunology Market, Global, 2016 – 2017, Roche
- Figure 2 11: Recent Events in the Immunology Market, Global, 2016 – 2017, Janssen
- Figure 2 12: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
- Figure 2 13: Recent Events in the Immunology Market, Global, 2016 – 2017, Merck
- Figure 2 14: Recent Events in the Immunology Market, Global, 2016 – 2017, Pfizer
- Figure 2 15: Recent Events in the Immunology Market, Global, 2016 – 2017, Takeda
- Figure 2 16: Recent Events in the Immunology Market, Global, 2016 – 2017, UCB
- Figure 2 17: Immunology Markets Covered, U.S., 2016 (1 of 2)
- Figure 2 18: Immunology Markets Covered, U.S., 2016 (2 of 2)
- Figure 2 19: Version History
- Figure 3 1: Classification by Mechanism of Action
- Figure 4 1: Marketed Product Portfolio by Company
- Figure 4 2: Marketed Product Portfolio by Company
- Figure 4 3: Marketed Product Portfolio by Company
- Figure 4 4: Marketed Product Portfolio by Company
- Figure 4 5: Marketed Product Portfolio by Company
- Figure 4 6: Marketed Product Portfolio by Company
- Figure 4 7: Marketed Product Portfolio by Company
- Figure 4 8: Marketed Product Portfolio by Company
- Figure 4 9: Marketed Product Portfolio by Company
- Figure 4 10: Marketed Product Portfolio by Company
- Figure 4 11: Marketed Product Portfolio by Company
- Figure 4 12: Marketed Product Portfolio by Company
- Figure 4 13: Other products in pipeline
- Figure 4 14: Pipeline Product Portfolio by Company (1 of 5)
- Figure 4 15: Pipeline Product Portfolio by Company (2 of 5)
- Figure 4 16: Pipeline Product Portfolio by Company (3 of 5)
- Figure 4 17: Pipeline Product Portfolio by Company (4 of 5)
- Figure 4 18: Pipeline Product Portfolio by Company (5 of 5)
- Figure 4 19: Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis (EQUIRA)
- Figure 4 20: Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab (RASTS)
- Figure 4 21: Prospective Study on Intensive Early Rheumatoid Arthritis Treatment (CURE)
- Figure 4 22: A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis
- Figure 4 23: Usability of an AI for M923 in Subjects With Moderate to Severe RA
- Figure 4 24: Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis
- Figure 4 25: Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus HUMIRA® for Treatment of Active Rheumatoid Arthritis
- Figure 4 26: PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis (rituximab)
- Figure 4 27: Abatacept Post-marketing Clinical Study in Japan
- Figure 4 28: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (ORAL STRATEGY)
- Figure 4 29: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
- Figure 4 30: An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 (RAPID-C OLE)
- Figure 4 31: A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Figure 4 32: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
- Figure 4 33: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
- Figure 4 34: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
- Figure 4 35: A Study Assessing the Safety and Efficacy of Subcutaneous Actemra®/RoActemra® Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
- Figure 4 36: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate in Participants With Moderate to Severe Active Rheumatoid Arthritis
- Figure 4 37: GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera® (ASSIST-RT)
- Figure 4 38: A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)
- Figure 4 39: A Study of Subcutaneous Actemra®/RoActemra® (Tocilizumab) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs
- Figure 4 40: Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
- Figure 4 41: A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)
- Figure 4 42: A Study of Actemra®/RoActemra® (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
- Figure 4 43: A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants
- Figure 4 44: A Study to Compare FKB327 Efficacy and Safety With HUMIRA® in Rheumatoid Arthritis Patients (ARABESC)
- Figure 4 45: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (RITACT)
- Figure 4 46: Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects
- Figure 4 47: A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis (RAPID-C)
- Figure 4 48: A Study on Safety and Efficacy of Tocilizumab (RoActemra® /Actemra ®) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (OSCAR)
- Figure 4 49: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Rheumatoid Arthritis (RA) (CHS-0214-02)
- Figure 4 50: A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra® /Actemra®) in Participants With Early Moderate to Severe Rheumatoid Arthritis
- Figure 4 51: Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
- Figure 4 52: A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
- Figure 4 53: To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)
- Figure 4 54: A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis
- Figure 4 55: A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
- Figure 4 56: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
- Figure 4 57: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
- Figure 4 58: Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
- Figure 4 59: Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease (RAPIDA)
- Figure 4 60: Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease (CALM)
- Figure 4 61: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
- Figure 4 62: Adalimumab-psoriasis and Small Bowel Lesions
- Figure 4 63: Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
- Figure 4 64: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
- Figure 4 65: Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease (TAILORIX)
- Figure 4 66: Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease
- Figure 4 67: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (APPRECIA)
- Figure 4 68: Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis
- Figure 4 69: A Study of Golimumab in Participants With Active Ankylosing Spondylitis
- Figure 4 70: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis
- Figure 4 71: Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS)
- Figure 4 72: The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) (GO-EASY)
- Figure 4 73: Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006) (GO-AHEAD)
- Figure 4 74: Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
- Figure 4 75: Phase 3 Study of M923 and HUMIRA® in Subjects With Chronic Plaque-type Psoriasis
- Figure 4 76: A Study of Golimumab in Participants With Active Psoriatic Arthritis
- Figure 4 77: MYL-1401A Efficacy and Safety Comparability Study to HUMIRA®
- Figure 4 78: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (CLEAR)
- Figure 4 79: Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis (PsOsim)
- Figure 4 80: Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis (IPSI-PSO)
- Figure 4 81: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)
- Figure 4 82: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)
- Figure 4 83: First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)
- Figure 4 84: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE) (JUNCTURE)
- Figure 4 85: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis (GAIN)
- Figure 4 86: Vascular Inflammation in Psoriasis - Extension Study (VIP-E)
- Figure 4 87: A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
- Figure 4 88: Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers (PSORITUS)
- Figure 4 89: Secukinumab in TNF-IR Psoriasis Patients. (SIGNATURE)
- Figure 4 90: Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
- Figure 4 91: Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)
- Figure 4 92: Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A
- Figure 4 93: Comparison of CHS-0214 to Enbrel® (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
- Figure 4 94: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)
- Figure 4 95: A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
- Figure 4 96: Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab (CARIMA)
- Figure 4 97: Adalimumab-psoriasis and Small Bowel Lesions
- Figure 4 98: Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND)
- Figure 4 99: Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
- Figure 4 100: Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and HUMIRA® (ADACCESS)
- Figure 4 101: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
- Figure 4 102: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis
- Figure 4 103: European Safety Registry in Ulcerative Colitis (Study P04808AM3)
- Figure 4 104: A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (OCTAVE)
- Figure 4 105: Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) (GO-COLITIS)
- Figure 4 106: Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD)
- Figure 4 107: A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis
- Figure 4 108: Adalimumab in the Treatment of Chronic Pouchitis (ADAP)
- Figure 4 109: Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) (SMART)
- Figure 4 110: A Long Term Safety Study of Infliximab (REMICADE®) in in Ulcerative Colitis Patients
- Figure 4 111: A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)
- Figure 4 112: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)
- Figure 4 113: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (InspirAda)
- Figure 4 114: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
- Figure 5 1: Prevalence of the autoimmune diseases in the U.S., 2017
- Figure 5 2: Treatment Population Size of Rheumatoid Arthritis, U.S., 2017
- Figure 5 3: Treatment Population Size of Crohn’s Disease, U.S., 2017
- Figure 5 4: Treatment Population Size of Ankylosing Spondilytis, U.S., 2017
- Figure 5 5: Treatment Population Size of Psoriasis, U.S., 2017
- Figure 5 6: Treatment Population Size of Ulcerative Colitis, U.S., 2017
- Figure 5 7: List of U.S. Retail Pharmacies
- Figure 5 8: Drug Prices - Retail Vs Veteran, 2017, U.S. (1 of 2)
- Figure 5 9: Drug Prices - Retail Vs Veteran, 2017, U.S. (2 of 2)
- Chart 5 10: Drug Prices - Retail Vs Veteran, 2017, U.S.
- Figure 6 1: Ulcerative Colitis Market by Segment, U.S., 2014 – 2024 (US$M)
- Figure 6 2: Ulcerative Colitis Market Growth by Segment, U.S., 2014 – 2024 (1 of 2)
- Figure 6 3: Leading Competitors, Ulcerative Colitis Market, U.S., 2017
- Figure 8 1: Press Release Summary